source
- Novo and Novartis see heart drug setbacks as trials show minimal efficacyNovo's cardiovascular candidate failed to demonstrate meaningful benefit in its pivotal study, causing the company's shares to fall about 9% in July. The trial data showed the drug had little effe…
- Amgen's Repatha shows reduced heart attack risk while Satellos alters Duchenne trial endpointSatellos Bioscience announced a change to the primary endpoint of its ongoing Duchenne muscular dystrophy trial of the investigational small‑molecule forazapadin, shifting focus to a measure of mus…